Therapies currently in preclinical development for prion disease seek to lower prion protein (PrP) expression in the brain. Trials of such therapies are likely to rely on quantification of PrP in cerebrospinal fluid (CSF) as a pharmacodynamic biomarker and possibly as a trial endpoint. Studies using...
ORGANISM(S): Homo Sapiens Rattus Norvegicus Mus Musculus Macaca Fascicularis
